Abstracts tagged "SLE"

Abstract Number: 1853 • 2015 ACR/ARHP Annual Meeting
Binding of a Novel IgG3 VH4-34 Monoclonal Antibody to ssRNA in SLE
Asiya Chida¹, Kevin Cashman¹, Scott Jenks², Louise Hartson¹, Youliang Wang¹, Quan-Zhen Li Li^3,4, Chandra Mohan⁵ and Ignacio Sanz^6,7, ¹Medicine, Emory University, Atlanta, GA, ²Rheumatology, Emory University School of Medicine, Atlanta, GA, ³Immunology, University of Texas Southwestern Medical Center, Dallas, TX, ⁴Department of Immunology and Microarray Core Facility, University of Texas Southwestern Medical Center, Dallas, TX, ⁵Biomedical Engineering, University of Houston, Houston, TX, ⁶Rheumatology, Emory University, Atlanta, GA, ⁷Medicine/Rheumatology, Emory University, Atlanta, GA
Background/Purpose: IgG antibodies expressing the idiotope for the 9G4 idiotype, the framework-1 hydrophobic patch (HP) of VH4-34, are expanded in SLE and provide a unique…
Abstract Number: 2923 • 2015 ACR/ARHP Annual Meeting
The Effects of Disease Activity and Mood Disorders on Cognitive Function in Systemic Lupus Erythematosus
Michelle Barraclough^1,2, Rebecca Elliott^2,3, Shane McKie^2,3, Ben Parker^1,2 and Ian N. Bruce^1,2, ¹Stopford Building, Arthritis Research UK Centre for Epidemiology, Centre for Musculoskeletal Research, Institute of Inflammation and Repair, Manchester Academic Health Science Centre, The University of Manchester, Manchester, United Kingdom, ²Central Manchester University Hospital NHS Foundation Trust and Manchester Academic Health Science Centre, NIHR Manchester Musculoskeletal Biomedical Research Unit, Manchester, United Kingdom, ³Stopford Building, Neuroscience and Psychiatry Unit, Institute of Brain and Behaviour and Mental Health, Manchester Academic Health Science Centre, The University of Manchester, Manchester, United Kingdom
Background/Purpose: Cognitive dysfunction (CD) significantly affects SLE patients with many contributing causal factors. The effect of disease activity on cognitive function remains unclear and currently…
Abstract Number: 3215 • 2015 ACR/ARHP Annual Meeting
Bim Suppresses the Development of SLE By Limiting Macrophage Inflammatory Responses
Fu-Nien Tsai¹ and Harris R. Perlman², ¹Medicine, Rhuematology, Northwestern University, Chicago, IL, ²Feinberg School of Medicine, Northwestern University, Chicago, IL
Background/Purpose: The Bcl-2 family guards the mitochondrial apoptotic pathway. Among numerous Bcl-2 antagonists, only the loss of Bim in mice leads to the development of…
Abstract Number: 721 • 2015 ACR/ARHP Annual Meeting
Geographic Differences in Demographics, Clinical Characteristics, and Standard of Care in Multinational Studies of Patients with Moderate to Severe Systemic Lupus Erythematosus
Richard Furie¹, M Khamashta², L Wang³, J Drappa³, W Greth³ and G Illei³, ¹Division of Rheumatology, North Shore - LIJ Health System, New York, NY, ²Graham Hughes Lupus Research Laboratory, The Rayne Institute, St Thomas' Hospital, London, United Kingdom, ³MedImmune, Gaithersburg, MD
Background/Purpose: Most randomized controlled trials (RCTs) in systemic lupus erythematosus (SLE) include stratification factors to ensure a balanced allocation of subgroups that might respond differently…
Abstract Number: 807 • 2015 ACR/ARHP Annual Meeting
High Levels of Serum IFN-Alpha Mark a Subgroup of SLE Patients with Distinct Immunophenotypic Features and Hyperresponsiveness to Toll-like Receptor Stimulation
Uma Thanarajasingam¹, Mark A. Jensen², Jessica M. Dorschner³ and Timothy B. Niewold³, ¹Division of Rheumatology, Mayo Clinic, Rochester, MN, ²Divsion of Rheumatology and Department of Immunology, Mayo Clinic, Rochester, MN, ³Division of Rheumatology and Department of Immunology, Mayo Clinic, Rochester, MN
Background/Purpose: IFN-alpha is a pathogenic factor in SLE. High serum interferon activity (IFN-high) marks a subgroup of SLE patients strongly associated with increased disease severity…
Abstract Number: 1750 • 2015 ACR/ARHP Annual Meeting
Identification of Autoantibody-Inducing CD4 T Cell (aiCD4 T cell) That Causes Systemic Lupus Erythematosus (SLE) As DOCK8+ CD4 T Cell: Proof of Concept of Self-Organized Criticality Theory
Shunichi Shiozawa¹, Yumi Miyazaki², Kazuko Shiozawa³ and Ken Tsumiyama², ¹Department of Medicine, Rheumatic Diseases Unit, Kyushu University Beppu Hospital, Beppu, Japan, ²Medicine, Rheumatic Diseases Unit, Kyushu University Beppu Hospital, Beppu, Japan, ³Rheumatic Diseases Center, Konan Kakogawa Hospital, Kakogawa, Japan
Background/Purpose: We have shown that repeated immunization with antigen causes systemic autoimmunity in mice otherwise not prone to spontaneous autoimmune diseases. Overstimulation of CD4 T…
Abstract Number: 1856 • 2015 ACR/ARHP Annual Meeting
Exosomes from Patients with Active Systemic Lupus Erythematosus Induce a Strong Inflammatory Response
Joo Youn Lee¹, Jin Kyun Park^1,2, Eun Young Lee³, Eun Bong Lee³ and Yeong Wook Song^1,2, ¹Department of Molecular Medicine and Biopharmaceutical Sciences, Graduate School of Convergence Science and Technology and College of Medicine Seoul National University, Seoul, South Korea, ²Division of Rheumatology, Department of Internal Medicine, Seoul National University, Seoul, South Korea, ³Division of Rheumatology, Department of Internal Medicine, Seoul National University Hospital, Seoul, South Korea
Background/Purpose: Exosomes are 60–150 nm membrane vesicles that are secreted by various cells into surrounding body fluids including blood and urine. As vehicles for intercellular…
Abstract Number: 2925 • 2015 ACR/ARHP Annual Meeting
Factors Associated with Early Damage Accrual in Patients with Systemic Lupus Erythematosus: 12-Month Preliminary Results from the Inception Cohort of the Multicenter Early Lupus Project
Matteo Piga¹, Fabiana Figus¹, Francesca Bellisai², Silvano Bettio³, Alessandra Bortoluzzi⁴, Laura Coladonato⁵, Fabrizio Conti⁶, Andrea Doria³, Mauro Galeazzi², Marcello Govoni⁴, Florenzo Iannone⁷, Annamaria Iuliano⁸, Marta Mosca⁹, Imma Prevete⁸, Gian Domenico Sebastiani⁸, Francesca Romana Spinelli¹⁰, Chiara Tani⁹ and Alessandro Mathieu¹, ¹University of Cagliari, Cagliari, Italy, ²University of Siena, Siena, Italy, ³Department of Medicine-DIMED, University of Padova, Padova, Italy, ⁴University of Ferrara, Ferrara, Italy, ⁵DIM, Rheumatology Unit, Bari, Italy, ⁶Rheumatology Unit, Department of Internal Medicine and Medical Specialties, Sapienza University of Rome, Rome, Italy, ⁷Interdisciplinary Department of Medicine (DIM), Rheumatology Unit, University of Bari, Bari, Italy, ⁸Osp. San Camillo, Roma, Italy, ⁹University of Pisa, Pisa, Italy, ¹⁰Sapienza University of Rome, Rome, Italy
Background/Purpose: Preventing organ damage is a major challenge in management of Systemic Lupus Erythematosus (SLE). Few data are available on factors related to development of…
Abstract Number: 3222 • 2015 ACR/ARHP Annual Meeting
Repeated Administration of Dapirolizumab Pegol (DZP) Appears Safe and Well Tolerated in Patients with Systemic Lupus Erythematosus (SLE) and Is Accompanied By an Improvement in Disease Activity: Results from a Phase 1 Study
Chris Chamberlain¹, Murray Urowitz^2,3, Julie Soranson¹, Mark Watling¹, Peter Colman¹, Olivier Harari¹, Thomas Dorner⁴ and Falk Hiepe⁴, ¹UCB Pharma, Slough, United Kingdom, ²University of Toronto, Toronto, ON, Canada, ³Rheumatology, U of Toronto, Toronto Western Hospital, Toronto, ON, Canada, ⁴Charité – Universitätsmedizin, Berlin, Germany
Background/Purpose: CD40 ligand (CD40L) regulates interactions between T cells, B cells, and antigen presenting cells. Considerable evidence suggests CD40L blockade might provide an effective treatment…
Abstract Number: 722 • 2015 ACR/ARHP Annual Meeting
Biomarkers/Pathways Discovery of Lupus Nephritis By Urine Proteomics
Michelle Petri¹, Wei Fu², Adnan Kiani¹, Lauren DeVine¹, Conover Talbot Jr.¹ and Robert Cole¹, ¹Johns Hopkins University School of Medicine, Baltimore, MD, ²Rheumatology, Johns Hopkins University School of Medicine, Baltimore, MD
Background/Purpose: We have previously validated several urine proteomic biomarkers for Lupus Nephritis (osteoprotegerin, MCP-1, VCAM-1 and urine TWEAK). In this discovery effort we looked for…
Abstract Number: 808 • 2015 ACR/ARHP Annual Meeting
Heritable Endotheliopathy and ApolipoproteinL1 Risk Traits in SLE
Ashira Blazer¹, Andrew Markham², Sara Rasmussen³, Jill P. Buyon⁴, H. Michael Belmont⁵, Shilpi Mehta-Lee⁶, Janet Nwaukoni⁴, Peter M. Izmirly⁷ and Robert Clancy⁴, ¹Division of Rheumatology, NYU School of Medicine, New York, NY, ²Medicine, New York University School of Medicine, New York, NY, ³Department of Medicine, Division of Rheumatology, New York University School of Medicine, New York, NY, ⁴Medicine, Division of Rheumatology, New York University School of Medicine, New York, NY, ⁵Hosp for Joint Disease, New York, NY, ⁶Obstetrics and Gynecology, New York University School of Medicine, New York, NY, ⁷Rheumatology, NYU School of Medicine, New York, NY
Background/Purpose: With higher prevalence of renal and cardiovascular diseases (CVD), as well as HTN, African American (AA) SLE patients experience accelerated damage accrual and excess…
Abstract Number: 1754 • 2015 ACR/ARHP Annual Meeting
BANK1 Controls the Development of SLE By Modulating TLR7 Signaling and Type I IFN-Induced Translation Initiation Pathway in B Cells
Ying-Yu Wu¹, Ramesh Kumar², Harini Bagavant¹ and Marta E. Alarcon Riquelme³, ¹Arthritis and Clinical Immunology, Oklahoma Medical Research Foundation, Oklahoma City, OK, ²Oklahoma Medical Research Foundation, Oklahoma Cty, OK, ³Arthritis & Clinical Immunology, Oklahoma Medical Research Foundation, Center for Genomics and Oncological Research Pfizer-University of Granada-Junta de Andalucia, Oklahoma City, OK
Background/Purpose: BANK1 is a susceptibility gene for SLE, and we have shown that stimulation of TLR9 agonist leads to a reduction in the activation of…
Abstract Number: 1858 • 2015 ACR/ARHP Annual Meeting
Serum Tartrate Resistant Acid Phosphatase (TRAP) Levels Are Decreased and Associated with Anti-Maa Antibodies in Systemic Lupus Erythematosus (SLE) Patients
Kathleen Borghoff¹, Andy Hollins², Michael J. Duryee¹, Ted R. Mikuls², Zhixin Zhang³, Kaihong Su⁴, Michelene Hearth-Holmes⁵ and Geoffrey M. Thiele⁶, ¹Internal Medicine Division of Rheumatology, University of Nebraska Medical Center, Omaha, NE, ²University of Nebraska Medical Center, Omaha, NE, ³Department of Pathology and Microbiology, University of Nebraska Medical Center, Omaha, NE, ⁴Pathology and Microbiology, University of Nebraska Medical Center, Omaha, NE, ⁵Division of Rheumatology, University of Nebraska College of Medicine and VA Nebraska Western Iowa Health Care System, Omaha, NE, ⁶Omaha VA Medical Center and University of Nebraska Medical Center, Omaha, NE
Background/Purpose: Previous studies have shown that patients with systemic lupus erythematosus (SLE) are prone to systemic osteoporosis, bone loss and fracture. Paradoxically, previous studies…
Abstract Number: 2929 • 2015 ACR/ARHP Annual Meeting
Diet and Glucocorticoid Treatment in Patients with SLE
Cecilia Lourdudoss¹, Johan Frostegård² and Ronald F. van Vollenhoven³, ¹Dept. of Medicine, ClinTRID, Karolinska institutet, Stockholm, Sweden, ²Karolinska Institutet, Section of Immunology and chronic disease, Institute of Environmental Medicine, Stockholm, Sweden, ³Department of Medicine, Unit for Clinical Therapy Research, Inflammatory Diseases (ClinTRID), The Karolinska Institute, Stockholm, Sweden
Background/Purpose: Relatively little is known about the link between diet and treatment results in SLE. Glucocorticoids (GC) are used to control active SLE but minimized…
Abstract Number: 3223 • 2015 ACR/ARHP Annual Meeting
Anifrolumab, an Anti-Interferon Alpha Receptor Monoclonal Antibody, in Moderate to Severe Systemic Lupus Erythematosus (SLE)
Richard Furie¹, JT Merrill², VP Werth^3,4, M Khamashta⁵, K Kalunian⁶, P Brohawn⁷, G Illei⁷, J Drappa⁷, L Wang⁷ and S Yoo⁸, ¹North Shore-LIJ Health System, New York, NY, ²Oklahoma Medical Research Foundation, Oklahoma City, OK, ³Philadelphia V.A. Medical Center, Philidelphia, PA, ⁴University of Pennsylvania, Philadelphia, PA, ⁵Graham Hughes Lupus Research Laboratory, The Rayne Institute, St Thomas' Hospital, London, United Kingdom, ⁶UCSD School of Medicine, La Jolla, CA, ⁷MedImmune, Gaithersburg, MD, ⁸Regenx Bio, Rockville, MD
Background/Purpose: The efficacy and safety of anifrolumab (ANIFR), a type I IFN receptor antagonist, were assessed in a Phase II, randomized, double-blind, placebo-controlled study in…

All abstracts accepted to ACR Convergence are under media embargo once the ACR has notified presenters of their abstract’s acceptance. They may be presented at other meetings or published as manuscripts after this time but should not be discussed in non-scholarly venues or outlets. The following embargo policies are strictly enforced by the ACR.

Accepted abstracts are made available to the public online in advance of the meeting and are published in a special online supplement of our scientific journal, Arthritis & Rheumatology. Information contained in those abstracts may not be released until the abstracts appear online. In an exception to the media embargo, academic institutions, private organizations, and companies with products whose value may be influenced by information contained in an abstract may issue a press release to coincide with the availability of an ACR abstract on the ACR website. However, the ACR continues to require that information that goes beyond that contained in the abstract (e.g., discussion of the abstract done as part of editorial news coverage) is under media embargo until 10:00 AM ET on November 14, 2024. Journalists with access to embargoed information cannot release articles or editorial news coverage before this time. Editorial news coverage is considered original articles/videos developed by employed journalists to report facts, commentary, and subject matter expert quotes in a narrative form using a variety of sources (e.g., research, announcements, press releases, events, etc.).

Violation of this policy may result in the abstract being withdrawn from the meeting and other measures deemed appropriate. Authors are responsible for notifying colleagues, institutions, communications firms, and all other stakeholders related to the development or promotion of the abstract about this policy. If you have questions about the ACR abstract embargo policy, please contact ACR abstracts staff at [email protected].